PHILADELPHIA, Feb. 14, 2011 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for ...

WEST LAFAYETTE, Ind. – A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients. Purdue University innovators ...

(Reuters) - A panel of advisers to the Food and Drug Administration recommended on Tuesday that the agency no longer support the marketing of calcitonin salmon as a treatment for osteoporosis in ...

Objective: To develop a method that estimates and compares the antifracture efficacy [relative risk reduction (RRR) and number needed to treat (NNT)] of various antiresorptive agents when fracture ...

In X-linked hypophosphatemia, phosphate wasting results from increased circulating levels of fibroblast growth factor 23 (FGF-23). 1 Administration of calcitonin to a patient with oncogenic ...

October 23, 2007 — Thyroid nodules are fairly common and, for the most part, are benign, but finding the ones that are not can be tricky. European studies have shown that routine measurement of serum ...

Data showed oral drug licensed from Unigene was as good as nasal spray calcitonin at improving BMD. Tarsa Therapeutics reported positive data from a Phase III study evaluating its once-daily oral ...

This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of ...

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice The study results demonstrate ...

-In response to recommendation regarding use of calcitonin-containing medicines, Company requesting access to safety data from relevant European products reviewed by CHMP- Ashleigh Palmer, Unigene's ...